Loading market dashboard
LENSAR, Inc.
LNSRHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026.
LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99,
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript
15 ALLY Robotic Cataract Laser Systems® (“ALLY Systems”) placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025
DexCom (NASDAQ: DXCM - Get Free Report) and LENSAR (NASDAQ: LNSR - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Volatility and Risk DexCom has a beta of 1.48, suggesting
In March 2025, Alcon agreed to acquire the laser solutions company for $14.00 per share for an aggregate implied value of approximately $356 million.
Beyond Meat (BYND) and LENSAR (LNSR) are among the names driving early action Tuesday as stock futures edge lower and oil prices move higher amid ongoing Iran r
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.
